Klaus Mantwill graduated in biology at the Christian Albrechts University in Kiel and investigated the influence of environmental toxins on the development of the immune system at the University of Cambridge (UK).
Later he pursued his main interest in cancer diagnosis and therapies, in Kiel on tumour markers for ovarian cancer and at the Charité, Berlin on drug resistance in cancer therapy.
Klaus Mantwill started developing oncolytic adenoviruses at the IOET (Institute for Experimental Oncology and Therapy) of the TU Munich in 2001. He was also task manager and researcher in the EU project (SaveMe) for the diagnosis and treatment of pancreatic cancer.
Since 2014, he has been investigating the molecular biological basis of oncolytic adenovirus therapy with a focus on the interaction between adenovirus and chemotherapy of cancer in the research department of urology.
Klaus Mantwill graduated in biology at the Christian Albrechts University in Kiel and investigated the influence of environmental toxins on the development of the immune system at the University of Cambridge (UK).
Later he pursued his main interest in cancer diagnosis and therapies, in Kiel on tumour markers for ovarian cancer and at the Charité, Berlin on drug resistance in cancer therapy.
Klaus Mantwill started developing oncolytic adenoviruses at the IOET (Institute for Experimental Oncology and Therapy) of the TU Munich in 2001. He was also task manager and researcher in the EU project (SaveMe) for the diagnosis and treatment of pancreatic cancer.
Since 2014, he has been investigating the molecular biological basis of oncolytic adenovirus therapy with a focus on the interaction between adenovirus and chemotherapy of cancer in the research department of urology.